Harnessing the potential of NK cell-based immunotherapies against multiple myeloma
Resumen: Natural killer (NK) cell-based therapies have emerged as promising anticancer treatments due to their potency as cytolytic effectors and synergy with concurrent treatments. Multiple myeloma (MM) is an aggressive B-cell malignancy that, despite development of novel therapeutic agents, remains incurable with a high rate of relapse. In MM, the inhospitable tumor microenvironment prevents host NK cells from exerting their cytolytic function. The development of NK cell immunotherapy works to overcome this altered immune landscape and can be classified in two major groups based on the origin of the cell: autologous or allogeneic. In this review, we compare the treatments in each group, such as autologous chimeric antigen receptor (CAR) NKs and allogeneic off-the-shelf NK cell infusions, and their combinatorial effect with existing MM therapies including monoclonal antibodies and proteasome inhibitors. We also discuss their placement in clinical treatment regimens based on the immune profile of each patient. Through this examination, we would like to discover precisely when each NK cell-based treatment will produce the maximum benefit to the MM patient.
Idioma: Inglés
DOI: 10.3390/cells11030392
Año: 2022
Publicado en: Cells 11, 3 (2022), 392 [17 pp.]
ISSN: 2073-4409

Factor impacto JCR: 6.0 (2022)
Categ. JCR: CELL BIOLOGY rank: 60 / 191 = 0.314 (2022) - Q2 - T1
Factor impacto CITESCORE: 9.0 - Medicine (Q1)

Factor impacto SCIMAGO: 1.537 - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA/B31-20R
Financiación: info:eu-repo/grantAgreement/ES/MCIN/AEI/10.13039/501100011033
Financiación: info:eu-repo/grantAgreement/ES/MICINN/PID2019-105128RB-I00
Tipo y forma: Article (Published version)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Exportado de SIDERAL (2023-09-13-12:15:47)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2022-03-22, last modified 2023-09-14

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)